公开(公告)号：EP1601349B1

公开(公告)日：2008-07-23

申请号：EP04711387.3

申请日：2004-02-16

申请人： PIERRE FABRE MEDICAMENT

发明人： DEREGNAUCOURT, Jean ,  GROSSE, Richard

IPC分类号： A61K31/135 ,  A61K31/165

CPC分类号： A61K31/135 ,  A61K31/165 ,  A61K31/167 ,  A61K31/195 ,  A61K31/4015 ,  Y10S514/81 ,  Y10S514/811 ,  Y10S514/812 ,  Y10S514/813 ,  A61K2300/00

公开(公告)号：EP0942731B1

公开(公告)日：2004-11-17

申请号：EP97952023.6

申请日：1997-11-25

申请人： MERCK SHARP & DOHME LTD.

发明人： BAKER, Raymond ,  CURTIS, Neil, Roy ,  ELLIOTT, Jason, Matthew ,  HARRISON, Timothy ,  HOLLINGWORTH, Gregory, John ,  JACKSON, Philip, Stephen ,  KULAGOWSKI, Janusz, Jozef ,  RUPNIAK, Nadia, Melanie ,  SEWARD, Eileen, Mary ,  SWAIN, Christopher, John ,  WILLIAMS, Brian, John

IPC分类号： A61K31/535 ,  A61K31/445

CPC分类号： A61K31/661 ,  A61K31/00 ,  A61K31/395 ,  A61K31/438 ,  A61K31/445 ,  A61K31/451 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/675 ,  C07D211/56 ,  C07D491/10 ,  Y10S514/81 ,  Y10S514/811 ,  Y10S514/812 ,  Y10S514/813

摘要： The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of substance use disorders, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising the same.

公开(公告)号：EP1007093B1

公开(公告)日：2003-10-29

申请号：EP97939680.1

申请日：1997-08-29

申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH

发明人： RENAULD, Jean-Christophe ,  MANY, Mary-Christine ,  HUAUX, François ,  LISON, Dominique

IPC分类号： A61K38/20 ,  A61P11/00 ,  A61P37/02

CPC分类号： A61K38/206 ,  A61K38/2026 ,  Y10S514/813 ,  Y10S514/86 ,  Y10S514/885 ,  A61K38/20 ,  A61K2300/00

摘要： A method for the treatment and prevention of immune disorders and fibrosis associated disorders is disclosed. The method involves administering interleukin-9 in an effective amount to the subject. Among the conditions treatable are thyroiditis, autoimmune diabetes and silicosis.

公开(公告)号：EP1019088B1

公开(公告)日：2003-02-12

申请号：EP98949758.1

申请日：1998-10-02

申请人： Cary Medical Corporation

发明人： CARY, Douglas, D.

IPC分类号： A61K31/135 ,  A61P25/34

CPC分类号： A61K31/135 ,  A61K45/06 ,  Y10S514/811 ,  Y10S514/812 ,  Y10S514/813 ,  A61K31/13 ,  A61K2300/00

摘要： The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HC1 and bupropion HC1) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

公开(公告)号：EP1130018A4

公开(公告)日：2003-01-15

申请号：EP99954381

申请日：1999-11-04

申请人： SANTEN PHARMA CO LTD

发明人： SUZUKI TSUTOMU ,  MITA SHIRO ,  MATSUNO KIYOSHI

IPC分类号： C07D295/096 ,  C07D295/08 ,  A61K31/495

CPC分类号： C07D295/096 ,  Y10S514/81 ,  Y10S514/811 ,  Y10S514/812 ,  Y10S514/813

摘要： Preventive or therapeutic agents for drug dependence, containing as the active ingredient 1,4-(diphenylalkyl)piperazine derivatives represented by general formula [I] or salts thereof, particularly preferably the one represented by general formula [II] or salts thereof, wherein R1 is lower alkoxy; R2 is lower alkoxy; A is lower alkylene; and B is lower alkylene.

公开(公告)号：EP1115402A1

公开(公告)日：2001-07-18

申请号：EP99939567.6

申请日：1999-09-03

申请人： Pfizer Products Inc.

发明人： JACKSON, Elise, Rose ,  MCLEAN, Stafford ,  ZORN, Stevin, Howard

IPC分类号： A61K31/505 ,  A61P25/16

CPC分类号： A61K31/4985 ,  A61K31/506 ,  A61K45/06 ,  Y10S514/81 ,  Y10S514/811 ,  Y10S514/812 ,  Y10S514/813 ,  Y10S514/866 ,  Y10S514/878 ,  Y10S514/879 ,  Y10S514/909

摘要： The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.

公开(公告)号：EP0954337A1

公开(公告)日：1999-11-10

申请号：EP97931953.0

申请日：1997-07-16

申请人： MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

发明人： RHODES, John ,  EVANS, Brian, Kenneth ,  RHODES, Peter ,  SANDBORN, William, Jeffery

IPC分类号： C07D401 ,  A61K9 ,  A61K31 ,  A61K38 ,  A61K47 ,  A61P25 ,  A61P29

CPC分类号： A61K9/4858 ,  A61K9/0031 ,  A61K9/4891 ,  A61K9/5026 ,  A61K31/4166 ,  A61K31/46 ,  A61K31/465 ,  A61K31/485 ,  A61K31/515 ,  A61K31/522 ,  A61K31/55 ,  A61K38/13 ,  A61K47/58 ,  A61K47/585 ,  Y10S514/813 ,  Y10S514/879

摘要： Nicotine is absorbed systemically from the intestine in therapeutic amounts for the treatment of nicotine responsive conditions, particularly inflammatory skin conditions, Alzheimer's disease, schizophrenia, Parkinson's disease, Tourette's syndrome, depression and to assist in the cessation of smoking. The nicotine is ideally delivered for absorption from the colon as a nicotine-polyacrylate complex in a sustained and delayed released enteric coated capsule. In this way, the high peak plasma levels, which normally give rise to side-effects associated with nicotine are reduced.

公开(公告)号：EP0915701A1

公开(公告)日：1999-05-19

申请号：EP97927159.0

申请日：1997-06-06

申请人： JANSSEN PHARMACEUTICA N.V.

发明人： GILIS, Paul, Marie, Victor ,  DE CONDE, Valentin, Florent, Victor

IPC分类号： A61K9 ,  A61K31 ,  A61P25 ,  A61P43

CPC分类号： A61K9/2054 ,  A61K9/2018 ,  A61K9/2027 ,  A61K31/55 ,  Y10S514/813 ,  Y10S514/879 ,  Y10S514/96

摘要： The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.

公开(公告)号：EP0440704B1

公开(公告)日：1995-10-11

申请号：EP89912045.5

申请日：1989-10-25

申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY

发明人： WURTMAN, Richard, J. ,  WURTMAN, Judith, J. ,  SPRING, Bonnie

IPC分类号： A61K31/00 ,  A61K31/135 ,  A61K31/15

CPC分类号： A61K31/00 ,  A61K31/135 ,  A61K31/15 ,  Y10S514/813

摘要： Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, nicotine withdrawal associated as well as experienced by individuals after discontinuing tobacco use as methods of use therefor. The compositions include serotoninergic drugs, such as d-fenfluramine and fluoxetine.

公开(公告)号：EP0663824A1

公开(公告)日：1995-07-26

申请号：EP92922828.0

申请日：1992-10-26

申请人： NEW YORK UNIVERSITY

发明人： CHERKSEY, Bruce

IPC分类号： A61K31 ,  A61P9 ,  A61P11 ,  A61P25 ,  C07D305 ,  C07D307 ,  C07D309 ,  C07D313

CPC分类号： A61K31/365 ,  Y10S514/812 ,  Y10S514/813

摘要： A method for activating potassium channels and for treating hypertension, addiction, asthma, incontinence, and other conditions treatable by potassium channel activators, comprising administering a compound having formula (I), wherein R is a saturated or unsaturated group having from 1 to 4 carbon atoms which is optionally substituted by lower alkyl, lower alkenyl or lower alkoxy groups; and wherein R' is hydrogen, lower alkyl, lower alkenyl, or aralkyl.